N/A N=400 Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects
Septal Defect, Atrial
Primary: Number of Subjects With 6-Month Composite Clinical Success — 332 Participants — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol
Atrial Septal Defect · Ventricular Septal Defect · Atrioventricular Septal Defect
Primary: L-citrulline Plasma Levels — 200.9; 34.1; 2405.9; 29.5 µmol/L
N/A N=411 Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation
Heart Failure · Atrial Fibrillation
Primary: Composite of All-cause Mortality and Heart Failure Events — 50; 64 Participants
N/A N=16 Comparative Efficacy of the Masquelet Versus Titanium Mesh Cage Techniques for the Treatment of Large Long Bone Defects
Segmental Long Bone Defects
Primary: Number of Participants With Defect Healing - Plain Radiography — 9; 7 Participants
N/A N=215 Long-term Safety Study of the GORE® HELEX® Septal Occluder
Septal Defect, Atrial
Primary: Efficacy — 180; 171; 9; 8 Participants
N/A N=1,000 Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder - Post Approval Study
Atrial Septal Defect
Primary: Percent of Subjects With Two-year Device-related Hemodynamic Compromise — 0.65 percentage of participants
Phase 4 N=54 Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter
Heart Rate and Rhythm Disorders
Primary: Percent of Patients Reaching Target HR<100bpm Within 30 Minutes — 46.4; 95.8 percentage of participants — p=.0001
Phase 2 N=260 Surgical Ablation Versus No Surgical Ablation for Patients With Atrial Fibrillation Undergoing Mitral Valve Surgery
Atrial Fibrillation · Mitral Valve Insufficiency · Mitral Valve Stenosis
Primary: Freedom From Atrial Fibrillation — 31.1; 61.8 percentage of patients
N/A N=10 On-pump Intraoperative Echocardiography
Septal Myectomy
Primary: Septal Thickness Measured Before Cardiopulmonary Bypass — 22.9; 22.5 millimeters
N/A N=16 Comparison of a Septal Stapler to Suture Closure in Nasal Septoplasty
Nasal Obstruction
Primary: Operative Time — 35; 423 seconds
N/A N=664 GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients
Stroke · Transient Ischemic Attack
Primary: Number of Subjects With Freedom From Recurrent Ischemic Stroke (Primary Outcome #1) — 6; 12 Participants — p=0.001
Phase 3 N=75 Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent
Atrial Fibrillation
Primary: Efficacy Endpoint: The Percent of Patients Off Class I or III Antiarrhythmic Drugs and Out of AF as Determined by 24 Hour Holter Recording at 9 Months — 42.6 percentage…
Phase 3 N=75 Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Study
Atrial Fibrillation
Primary: Efficacy Endpoint: The Percent of Patients Off Class I and/or III Antiarrhythmic Drugs and Out of Atrial Fibrillation as Determined by 24 Hour Holter Recording Conducted…
N/A N=111 Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation
Mitral Valve Insufficiency · Atrial Fibrillation · Heart Failure
Primary: Left Ventricular Filling Pressure More Than 15 mmHg Measured by Left Ventricular Catheterization — 25.5 mmHg
N/A N=12 Dabigatran Adherence Pilot Intervention for Patients With Atrial Fibrillation
Atrial Fibrillation
Primary: Gaps Days Between Prescription Refills for Dabigatran, Rivaroxaban, and Apixaban — 43; 51; 41; -5 days